AbbVie Inc. (NYSE:ABBV) traded at $83.41 at last check on Monday, Oct 26, making a downturn move of -1.1% on its previous day’s price.
Looking at the stock we see that its previous close was $84.34 and the beta (5Y monthly) reads 0.67 with the day’s price range being $82.81 – 84.32. The company has a 12-month trailing PE ratio of 18.55. In terms of its 52-week price range, ABBV has a high of $101.28 and a low of $62.55. The company’s stock has gained about -1.83% over that past 30 days.
AbbVie has a market cap of $148.79 Billion and is expected to release its quarterly earnings report on October 30, 2020. With its Forward Dividend at 4.72 and a yield of 5.6%, the company’s investors could be anxious for the ABBV stock to gain ahead of the earnings release. Estimates by analysts give the company expected earnings per share (EPS) of $2.77, with the EPS growth for the year raised at $10.44 for 2020 and $12.14 for next year. These figures represent 0.17% and at 0.16% growth in EPS for the two years respectively.
Analysts tracking the company’s growth have also given it a consensus growth in revenue estimated at $12.77 Billion, with a low of $12.5 Billion and a high of $12.89 Billion. The median projection represents growth adding up to 50.6% compared to sales earnings for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecasts for 2020 are expected to hit $45.53 Billion, or +36.9% up from figures reported last year.
There have been 3 upward and no downward revisions for the stock’s EPS in last 7 days, something that reflects the nature of company’s price movement in short term. On the other hand, looking at the outlook for the ABBV stock, short term indicators assign the stock an average of 100% Sell, while medium term indicators assign it an average of 50% Sell. Long term indicators on average place the stock in the category of 50% Sell.
Based on estimates by 21 analysts where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 5 have rated the AbbVie Inc. (ABBV) stock as a Hold, while 14 rate it as a Buy. 2 analysts rate it as outperform while none of them rated it as underperform, whereas none suggests the stock as a Sell. The stock has an overall rating of Overweight and investors could take advantage and scoop up stock of the company.
Looking further, we note that the PEG ratio for the ABBV stock currently stands at 1.98, and the current price level is -3.28% off its SMA20 and -7% from its 50-day simple moving average. The RSI (14) is pointing at 36.33 while the volatility over the past week is 2.12% and drops to 1.75% over the past one month. The beta value is 0.67, while the average true range (ATR) is currently pointing at 1.68. The average price target for the stock over the next 12 months is $109.61, with the estimates having a low of $96 and a high of $127. These price ends are 15.09% and +52.26% off the current price level respectively, although investors could be excited at the prospect of a +31.88% if the ABBV share price touches on the median price of $110.
Let’s briefly compare AbbVie (ABBV) stock to its peers. We find that today’s price change of -1.1% and +9.82% over the past 12 months for ABBV competes that of Johnson & Johnson (JNJ), which has seen its stock price fall -1.4% in the latest trading session and is +13.91% over the last one year. Another of its peers Pfizer Inc (PFE) has dropped -1.61% today, and is +4.92% up over the past year, while Merck & Company (MRK) is also down -1.1% yet its price remains in the green at 9.82% over the same period. Johnson has a P/E ratio of 23.24 compared to AbbVie’s 18.55 and Pfizer’s 15.54. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial are today at -2.04% and -2.53%, respectively, in early deals.
Coming back to AbbVie Inc. (NYSE:ABBV), we note that the average 3-month trading volume was 7.16 Million, while that of the preceding 10-day period stands at 7.45 Million. Current shares outstanding are 1.76 Billion.
According to data from Thomson Reuters, insiders hold 0.11% of the company’s shares while institutions hold 76.76%. The data shows that short shares as of September 29, 2020, stood at 12.94 Million at a short ratio of 1.62. This represents a 0.73% Short interest in Shares outstanding on September 29, 2020. Shares short rose in September from the previous month at 12.16 Million. Investors should be excited about this stock as its upside potential is great, with today’s price pushing the stock -4.74% down in year-to-date price movement.